•
Shenzhen-based QuantumPharm Inc. (HKG: 2228), also known as Xtalpi Inc., announced a strategic investment in Alternative Bio, alongside an in-depth research partnership with the Wuxi-based biotech firm. Alternative Bio’s Innovative Drug DevelopmentAlternative Bio, founded by three serial entrepreneur scientists, focuses on developing small molecule targeted innovative drugs for major diseases…
•
China-based ClouDr Group Limited (HKG: 9955) announced the integration of the DeepSeeker R1 model into its exclusive medical artificial intelligence (AI) product, CloudrBrain. The move aims to enhance CloudrBrain’s digital mining capabilities and improve the efficiency of chronic disease management through its hospital SaaS and pharmacy SaaS solutions. Enhancing AI-Driven…
•
DeepSeek, a Chinese artificial intelligence company, is poised to make a significant impact on the pharmaceutical industry through its advanced natural language processing (NLP) and large language model (LLM) technologies. The potential applications span multiple dimensions, including data-driven research, clinical decision-making, and resource management. This analysis explores the potential impacts…
•
In the regulatory submissions for Investigational New Drug (IND) and New Drug Application (NDA) in the biopharmaceutical sector, DeepSeek, as an AI technology tool or service platform, can enhance the efficiency and compliance of the application process through the following means: Data Management and Analysis Document Automation and Compliance Support…
•
US-based Eli Lilly and Company (NYSE: LLY) and Merck & Co. Inc. (NYSE: MRK) have announced the launch of the Young Institute Pharmaceutical Manufacturing Consortium in collaboration with Purdue University. The initiative aims to develop new methods of drug manufacturing, driving technological innovation in the pharmaceutical industry. Consortium Focus and…
•
US-based genomics giant Illumina (NASDAQ: ILMN) has announced a strategic partnership with chip manufacturer NVIDIA (NASDAQ: NVDA) to advance technology platforms for the analysis and interpretation of multiomic data. This collaboration aims to accelerate progress in clinical research, genomics AI development, and drug discovery, leveraging the strengths of both companies…
•
Partners Novo Nordisk (NYSE: NVO) and Valo Health have announced an expanded partnership, aiming to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease. The collaboration leverages Valo’s extensive human dataset and computation powered by artificial intelligence (AI) to accelerate the development of innovative therapies. Initial…
•
US-based science and tech services giant Danaher Corporation (NYSE: DHR) has announced an investment partnership with Innovaccer Inc., a leading Silicon Valley-based healthcare artificial intelligence (AI) company. The alliance is designed to improve patient prognosis and experience through innovative digital solutions. Innovaccer’s SolutionsInnovaccer offers a suite of software solutions designed…
•
Zhejiang-based BrainAurora Medical Technology Limited (HKG: 6681), the first company in China to combine neuroscience and artificial intelligence (AI) technology for developing medical-grade digital therapy products, has successfully completed an initial public offering (IPO) of 181,112,000 shares on the Hong Kong Stock Exchange. The offering, priced at HKD 3.22 per…
•
China-based Shanghai Fourier Intelligence Co., Ltd, a leading developer of exoskeleton robotic products for rehabilitation and orthoses, has reportedly raised close to RMB 800 million (USD 109 million) in a Series E financing round. The round was backed by prominent investors including Guoxin Investment, PDVC, Zhangjiang S&T Investment, Prosperity7, PEAKVEST,…
•
Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., has announced that its subsidiary Ailux Biologics has struck a partnership with UCB (EBR: UCB), granting the Belgian biopharma commercial rights to utilize Ailux’s XtalFold AI platform for the discovery and engineering design of macromolecular drugs. No financial details were…
•
PostEra, a Boston-based biotech company powered by machine learning, has announced an expanded partnership with US pharmaceutical giant Pfizer (NYSE: PFE). The collaboration includes the launch of a new antibody drug conjugate (ADC) program, as well as the expansion of an existing USD 260 million AI Lab collaboration project. Financial…
•
Quris AI, an artificial intelligence (AI) pharmaceutical company based in Boston and Tel-Aviv, has announced that Merck KGaA (ETR: MRK) has adopted its Bio-AI clinical prediction platform as part of the German major’s drug development pipeline. This means that selected preclinical small molecule candidates will now be tested through the…
•
Shenzhen-based QuantumPharm Inc., operating under the name Xtalpi Inc. (HKG: 2228), has announced a strategic partnership with US-based Amazon Web Services (AWS). AWS will serve as Xtalpi’s cloud service provider, empowering the company to enhance its innovative development in life science, chemistry, and new materials through the use of artificial…
•
China-based We Doctor Holdings Limited, a subsidiary of Chinese internet giant Tencent Corporate Venture Capital (HKG: 0700), has made an initial public offering (IPO) filing with the Hong Kong Stock Exchange. At this stage, no unit price or additional details have been disclosed. We Doctor’s AI-Based Healthcare SolutionsWe Doctor offers…
•
China’s Shanghai Ark Biopharmaceutical Co., Ltd. has formed a strategic alliance with Germany-based Partex, an artificial intelligence (AI)-empowered drug developer. This partnership aims to explore the potential of AK0707, an autotaxin inhibitor developed in-house by Ark Bio. Partex will utilize its AI-driven platform to uncover potential indications for the drug.…
•
Shenzhen-based QuantumPharm Inc., trading under the name Xtalpi Inc. (HKG: 2228), has announced a strategic partnership with the National Cancer Center Singapore (NCCS) and Duke-NUS Medical School. This collaboration will harness the power of artificial intelligence (AI) to revolutionize the discovery and design of clinical drug candidates. AI-Driven Peptide Research…
•
China-based Xbiome, an AI-driven microbiome drug development company, has announced a strategic alliance with Australia-headquartered ZoHealth. This collaboration focuses on the development of human gut microbiota, precision nutrition, and health product innovation. Core Program Focused on Probiotic ProductsThe core program of the partnership will center around Xbiome’s proprietary bacterial strains,…
•
US-based Boston Scientific Corporation (NYSE: BSX) has announced that China’s National Medical Products Administration (NMPA) has granted approval for its next-generation intravascular ultrasound (IVUS) diagnostic system, AVVIGO+, for use in diagnosing coronary heart disease. This marks a significant advancement in the diagnostic capabilities for cardiovascular healthcare in China. Multimodal Platform…
•
Shenzhen-based QuantumPharm Inc., trading as Xtalpi Inc. (HKG: 2228), has announced a strategic partnership with Gnosis Neurodynamics, a leading brain science artificial intelligence (AI) company in China. This collaboration aims to harness AI algorithms and EEG BioMarker recognition models to develop a state-of-the-art neural drug screening platform. The platform will…